A carregar...
5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology
Phosphoinositide 3-kinase (PI3K) is deregulated in a wide variety of human tumors and triggers activation of protein kinase B (PKB/Akt) and mammalian target of rapamycin (mTOR). Here we describe the preclinical characterization of compound 1 (PQR309, bimiralisib), a potent 4,6-dimorpholino-1,3,5-tri...
Na minha lista:
Publicado no: | J Med Chem |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , , , |
Formato: | Artigo |
Idioma: | Inglês |
Publicado em: |
2017
|
Assuntos: | |
Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5656176/ https://ncbi.nlm.nih.gov/pubmed/28829592 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acs.jmedchem.7b00930 |
Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|